{
    "Clinical Trial ID": "NCT00436917",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Zoledronic Acid",
        "  4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Diagnosis of localized breast cancer",
        "  Stage I-IIIA disease",
        "  Adequately treated breast cancer",
        "  No clinical or radiological evidence of recurrent or metastatic disease",
        "  Baseline total lumbar spine or femoral neck bone mineral density T-score < -2.0 standard deviation (e.g., a patient with a T score of -2.1 is eligible)",
        "  Hormone-receptor status:",
        "  Estrogen receptor and/or progesterone receptor-positive breast cancer",
        "  PATIENT CHARACTERISTICS:",
        "  Female",
        "  Postmenopausal, defined by 1 of the following criteria:",
        "  Age > 55 years with cessation of menses",
        "  Age  55 years with spontaneous cessation of menses for > 1 year",
        "  Age  55 years with spontaneous cessation of menses for  1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy), AND has postmenopausal estradiol levels",
        "  Bilateral oophorectomy",
        "  ECOG performance status 0-2",
        "  Life expectancy  5 years",
        "  WBC  3,000/mm\u00b3 OR granulocyte count  1,500/mm\u00b3",
        "  Platelet count  100,000/mm\u00b3",
        "  Alkaline phosphatase  3 times upper limit of normal (ULN)",
        "  AST  3 times ULN",
        "  Creatinine < 2.0 mg/dL",
        "  Creatinine clearance  45 mL/min",
        "  No hypercalcemia (i.e., calcium level > 1 mg/dL above ULN) OR hypocalcemia (i.e., calcium level > 0.5 mg/dL below lower limit of normal) within the past 6 months",
        "  No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix",
        "  No other nonmalignant systemic diseases, including any of the following:",
        "  Uncontrolled infection",
        "  Uncontrolled diabetes mellitus",
        "  Uncontrolled thyroid dysfunction",
        "  Disease affecting bone metabolism (hyperparathyroidism, hypercortisolism, Paget's disease, osteogenesis imperfecta)",
        "  Malabsorption syndrome",
        "  No uncontrolled seizure disorders associated with falls",
        "  No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or vitamin D",
        "  No concurrent active dental problems, including any of the following:",
        "  Infection of the teeth or jawbone (maxillary or mandibular)",
        "  Dental or fixture trauma",
        "  Prior or current diagnosis of osteonecrosis of the jaw",
        "  Exposed bone in the mouth",
        "  Slow healing after dental procedures",
        "  No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following:",
        "  History of surgery at the lumbosacral spine, with or without implantable devices",
        "  Scoliosis with a Cobb angle > 15 degrees at the lumbar spine",
        "  Immobility, hyperostosis, or sclerotic changes at the lumbar spine, or evidence of sclerotic abdominal aorta sufficient to interfere with DXA scan",
        "  Disease of the spine that would preclude the proper acquisition of a lumbar spine DXA",
        "  No condition that would preclude study follow-up or compliance",
        "  No psychiatric illness that would preclude giving informed consent",
        "  PRIOR CONCURRENT THERAPY:",
        "  More than 3 weeks since prior and no other concurrent oral bisphosphonates",
        "  No prior intravenous bisphosphonates",
        "  No prior aromatase inhibitor therapy",
        "  More than 6 months since prior anabolic steroids or growth hormone",
        "  More than 2 weeks since prior and no concurrent inhibitor of osteoclastic bone resorption (e.g., calcitonin, mithramycin, or gallium nitrate)",
        "  More than 30 days since prior systemic investigational drug and/or device",
        "  More than 7 days since prior topical investigational drug",
        "  More than 6 weeks since prior and no concurrent dental or jaw surgery (e.g., extraction, implants)",
        "  Concurrent short-term corticosteroid therapy allowed",
        "  No concurrent sodium fluoride, parathyroid hormone, or tibolone",
        "  No other concurrent investigational drug or device"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD)",
        "  Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value.",
        "  Time frame: Baseline and 1 year",
        "Results 1: ",
        "  Arm/Group Title: Zoledronic Acid",
        "  Arm/Group Description: 4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)",
        "  Overall Number of Participants Analyzed: 30",
        "  Mean (95% Confidence Interval)",
        "  Unit of Measure: Percentage of the baseline value  2.66        (1.27 to 4.62)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/52 (1.92%)",
        "  Musculoskeletal disorder 1/52 (1.92%)"
    ]
}